Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03580525 · ClinicalTrials.gov registry record · Early Phase 1
Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT03580525 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 24 participants.
The verdict
NCT03580525, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
A placebo-controlled study to enroll male and female tobacco smokers who will participate in five experimental sessions. subjects will be given an IV infusion of either saline or 1 mg nicotine at rapid, moderate or slow infusion rates (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body weight per sec).
Interventions
- DRUG Nicotine saline infusion 0.00mcg/kg/s
- DRUG Nicotine infusion 0.24mcg/kg/s
- DRUG Nicotine infusion 0.096mcg/kg/s
- DRUG Nicotine infusion 0.048 mcg/kg/s
- DRUG Nicotine infusion 0.024mcg/kg/s
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-02-14 |
| Est. Completion | 2020-11-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03580525
The ClinicalTrials.gov registry entry for NCT03580525 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nicotine saline infusion 0.00mcg/kg/s is the first listed.
NCT03580525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03580525 about?
NCT03580525 is a clinical study titled "Nicotine Delivery Rate and Its Abuse Potential: Impact of Menthol". A placebo-controlled study to enroll male and female tobacco smokers who will participate in five experimental sessions. subjects will be given an IV infusion of either saline or 1 mg nicotine at rapid, moderate or slow infusion rates (nicotine at 0.24,0.096, 0.048 and 0.024, mcg per kg body weight ...
What is the current status of trial NCT03580525?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2019-02-14. Estimated completion is 2020-11-19.
What interventions are being tested in trial NCT03580525?
The interventions under investigation include: Nicotine saline infusion 0.00mcg/kg/s (DRUG), Nicotine infusion 0.24mcg/kg/s (DRUG), Nicotine infusion 0.096mcg/kg/s (DRUG), Nicotine infusion 0.048 mcg/kg/s (DRUG), Nicotine infusion 0.024mcg/kg/s (DRUG).
Who is sponsoring clinical trial NCT03580525?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.